October 18, 2010 11:44 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
After the close on Friday, 10/15/10, Allergan, Inc. (NYSE: AGN) announced that the FDA approved Botox for chronic migraine (CM), Wells Fargo reports, noting that the approval came a few weeks sooner than we expected.“We view this news very positively because we believe the CM indication will contribute about $500MM in incremental sales to AGN by 2014 and will increase AGN's 2010-2014 sales CAGR by 200bps (6.8% vs 4.8%),” Wells Fargo writes.“The CM indication will very likely augment AGN's EPS growth by a greater degree given the low level of incremental investment needed to drive CM sales because AGN is already promoting Botox to neurologists for other indications.”Allergan currently trades for $71.88.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.